Market Place
Sourcing Support
Matica Biotechnology Establishes CDMO Partnership with KaliVir
24 Oct 2024 //
BUSINESSWIRE
Marinus Strengthens IP Estate With Patent For ZTALMY® Regimens
15 Oct 2024 //
BUSINESSWIRE
Marinus Pharma Announces Presentations At NCS 2024 Meeting
09 Oct 2024 //
BUSINESSWIRE
Marinus Pharmaceuticals to Highlight Clinical Progress
20 Sep 2024 //
BUSINESSWIRE
Marinus Pharmaceuticals Announces Investor & Analyst Day Agenda
12 Sep 2024 //
BUSINESSWIRE
Marinus To Present At Cantor Global Healthcare Conference
10 Sep 2024 //
BUSINESSWIRE
Marinus Pharma Reports Q2 2024 Results And Business Update
13 Aug 2024 //
BUSINESSWIRE
Ganaxolone Approved In China For CDKL5 Deficiency Disorder Seizures
18 Jul 2024 //
BUSINESSWIRE
Marinus Pharma Announces Topline Results From Phase 3 RAISE Trial Of Ganaxolone
17 Jun 2024 //
BUSINESSWIRE
Marinus lays off 20% to steady ship after IV seizure med issues
08 May 2024 //
FIERCE BIOTECH
Marinus Q1 2024 Results, Business Update On May 8
01 May 2024 //
BUSINESSWIRE
Marinus seizure med fails at interim analysis; shares plummet
16 Apr 2024 //
FIERCE PHARMA
Marinus RAISE Update, Prelim Q1 2024 Results
15 Apr 2024 //
BUSINESSWIRE
Marinus Initiates Global Access Program for ZTALMY Oral Suspension CV
07 Nov 2023 //
BUSINESSWIRE
Marinus Announces EC Approval of ZTALMY for Epileptic Seizures
01 Aug 2023 //
BUSINESSWIRE
Marinus Announces New Method of Use Patent Granted for IV Ganaxolone
21 Jun 2023 //
BUSINESSWIRE
Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY
26 May 2023 //
BUSINESSWIRE
Marinus Pharmaceuticals Reports Q4 and Full Year 2022 ZTALMY
05 Jan 2023 //
BUSINESSWIRE
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
Marinus Announces Collaboration with Tenacia for Ganaxolone Development
17 Nov 2022 //
BUSINESSWIRE
Marinus Pharmaceuticals Provides Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Marinus Pharma Announces U.S. Commercial Launch of ZTALMY
28 Jul 2022 //
BUSINESSWIRE
Marinus Pharma to Publish ZTALM Phase 3 Marigold Trial Results
14 Apr 2022 //
BUSINESSWIRE
Marinus Pharmaceuticals Gets FDA Approval for Ztalmy
19 Mar 2022 //
BLOOMBERG LAW
Marinus Pharma Announces Delay to RAISE Phase 3 Trial in Status Epilepticus
22 Feb 2022 //
BUSINESSWIRE
FDA Accepts Marinus` NDA for Ganaxolone in CDKL5 Deficiency Disorder
20 Sep 2021 //
BUSINESSWIRE
European Medicines Agency Grants Marinus Accelerated Assessment of Ganaxolone
26 Aug 2021 //
BUSINESSWIRE
Marinus Pharmaceuticals reports topline Phase 2 results and bags FDA ODD status.
17 Aug 2021 //
BUSINESSWIRE
Marinus Provides Additional Ganaxolone During Scientific Exhibit at AES2020
07 Dec 2020 //
BUSINESSWIRE
Marinus closing in on launch of pivotal study of ganaxolone
24 Sep 2020 //
SEEKING ALPHA
Marinus Receives Rare Pediatric Disease Designation from FDA for Ganaxolone
30 Jul 2020 //
BIOSPACE
Marinus Receives Rare Pediatric Disease Designation from FDA for Ganaxolone
30 Jul 2020 //
BUSINESSWIRE
